Overview

A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Status:
Recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Phase:

Phase 3

Details

Lead Sponsor:

Clovis Oncology, Inc.

Collaborator:

Foundation Medicine

Treatments:

Abiraterone Acetate
Docetaxel
Rucaparib